ORCHPHARMAPharmaceuticals
Orchid Pharma Ltd — PE Ratio & Valuation Analysis
₹482.45
-5.52%
Current P/E83.18xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E65.4x27.2% above avg
⚠️
161.8% Premium to Industry
ORCHPHARMA P/E 83.18x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹19.65 | ₹759 | 38.6x |
| 2024 | ₹19.06 | ₹1807 | 94.8x |
| 2023 | ₹11.35 | ₹713 | 62.8x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Orchid Pharma Ltd Valuation
Orchid Pharma Ltd (ORCHPHARMA) currently trades at 83.18x earnings. The Pharmaceuticals sector average PE is 31.77x. ORCHPHARMA commands a premium, reflecting high growth expectations. Historically, ORCHPHARMA has traded at an average PE of 65.4x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
8.21%
Dividend Yield
0.00%
More on Orchid Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.